Cargando…
Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer
BACKGROUND: There was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC). METHODS: The clinical charts of 233 patients with CRPC treated with enzalutamide were...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486121/ https://www.ncbi.nlm.nih.gov/pubmed/34597353 http://dx.doi.org/10.1371/journal.pone.0258160 |
_version_ | 1784577677397590016 |
---|---|
author | Tsuzuki, Shunsuke Nakanishi, Shotaro Tamaki, Mitsuyoshi Oshiro, Takuma Miki, Jun Yamada, Hiroki Shimomura, Tatsuya Kimura, Takahiro Furuta, Nozomu Saito, Seiichi Egawa, Shin |
author_facet | Tsuzuki, Shunsuke Nakanishi, Shotaro Tamaki, Mitsuyoshi Oshiro, Takuma Miki, Jun Yamada, Hiroki Shimomura, Tatsuya Kimura, Takahiro Furuta, Nozomu Saito, Seiichi Egawa, Shin |
author_sort | Tsuzuki, Shunsuke |
collection | PubMed |
description | BACKGROUND: There was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC). METHODS: The clinical charts of 233 patients with CRPC treated with enzalutamide were reviewed retrospectively. After 1:3 propensity score matching (PSM), 124 patients were divided into a reduced dose group and a standard dose group, and the prostate specific antigen (PSA) response and the incidence of AEs were compared. RESULTS: 190 patients with CRPC initiated with standard dose enzalutamide were younger and better performance status compared with 43 patients beginning with reduced dose. After PSM, the baseline characteristics were not different between the standard and the reduced dose group. In the PSM cohort, the PSA response rate was significantly lower in the reduced dose group than in the standard dose group (-66.3% and -87.4%, p = 0.02). The incidence rates of AEs were not statistically different between the groups (22.6% and 34.4%, respectively, p = 0.24). CONCLUSION: Initiating treatment with a reduced dose of enzalutamide did not significantly decrease the incidence rate of AEs, and it showed poorer PSA response rate. There is no clear rationale for treating with a reduced initial dose of enzalutamide to reduce the incidence of AEs. |
format | Online Article Text |
id | pubmed-8486121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-84861212021-10-02 Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer Tsuzuki, Shunsuke Nakanishi, Shotaro Tamaki, Mitsuyoshi Oshiro, Takuma Miki, Jun Yamada, Hiroki Shimomura, Tatsuya Kimura, Takahiro Furuta, Nozomu Saito, Seiichi Egawa, Shin PLoS One Research Article BACKGROUND: There was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC). METHODS: The clinical charts of 233 patients with CRPC treated with enzalutamide were reviewed retrospectively. After 1:3 propensity score matching (PSM), 124 patients were divided into a reduced dose group and a standard dose group, and the prostate specific antigen (PSA) response and the incidence of AEs were compared. RESULTS: 190 patients with CRPC initiated with standard dose enzalutamide were younger and better performance status compared with 43 patients beginning with reduced dose. After PSM, the baseline characteristics were not different between the standard and the reduced dose group. In the PSM cohort, the PSA response rate was significantly lower in the reduced dose group than in the standard dose group (-66.3% and -87.4%, p = 0.02). The incidence rates of AEs were not statistically different between the groups (22.6% and 34.4%, respectively, p = 0.24). CONCLUSION: Initiating treatment with a reduced dose of enzalutamide did not significantly decrease the incidence rate of AEs, and it showed poorer PSA response rate. There is no clear rationale for treating with a reduced initial dose of enzalutamide to reduce the incidence of AEs. Public Library of Science 2021-10-01 /pmc/articles/PMC8486121/ /pubmed/34597353 http://dx.doi.org/10.1371/journal.pone.0258160 Text en © 2021 Tsuzuki et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Tsuzuki, Shunsuke Nakanishi, Shotaro Tamaki, Mitsuyoshi Oshiro, Takuma Miki, Jun Yamada, Hiroki Shimomura, Tatsuya Kimura, Takahiro Furuta, Nozomu Saito, Seiichi Egawa, Shin Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer |
title | Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer |
title_full | Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer |
title_fullStr | Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer |
title_full_unstemmed | Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer |
title_short | Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer |
title_sort | initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486121/ https://www.ncbi.nlm.nih.gov/pubmed/34597353 http://dx.doi.org/10.1371/journal.pone.0258160 |
work_keys_str_mv | AT tsuzukishunsuke initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT nakanishishotaro initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT tamakimitsuyoshi initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT oshirotakuma initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT mikijun initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT yamadahiroki initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT shimomuratatsuya initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT kimuratakahiro initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT furutanozomu initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT saitoseiichi initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer AT egawashin initialdosereductionofenzalutamidedoesnotdecreasetheincidenceofadverseeventsincastrationresistantprostatecancer |